Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | +5.61% | +7.36% | -7.76% |
May. 16 | HCW Biologics Inc. announced that it expects to receive $10 million in funding | CI |
May. 15 | HCW Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 82.89 | 68.69 | 44.07 | 40.47 | - | - |
Enterprise Value (EV) 1 | 82.89 | 68.69 | 44.07 | 40.47 | 40.47 | 40.47 |
P/E ratio | -3.36 x | -4.56 x | -1.75 x | -1.73 x | -1.95 x | -1.7 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | 10.2 x | 15.5 x | 35.9 x | - | - |
EV / Revenue | - | 10.2 x | 15.5 x | 35.9 x | - | - |
EV / EBITDA | - | -5,187,530 x | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 35,728 | 35,871 | 35,975 | 37,823 | - | - |
Reference price 2 | 2.320 | 1.915 | 1.225 | 1.070 | 1.070 | 1.070 |
Announcement Date | 3/29/22 | 3/28/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 4.1 | - | 6.722 | 2.842 | 1.127 | - | - |
EBITDA | - | - | -13.24 | - | - | - | - |
EBIT 1 | - | -13.37 | -15.08 | -25.72 | -25.88 | -29.6 | -38.48 |
Operating Margin | - | - | -224.32% | -904.96% | -2,296.45% | - | - |
Earnings before Tax (EBT) 1 | - | -12.86 | -14.9 | -24.99 | -25.86 | -29.6 | -38.48 |
Net income 1 | - | -12.86 | -14.9 | -24.99 | -25.86 | -29.6 | -38.48 |
Net margin | - | - | -221.67% | -879.53% | -2,294.23% | - | - |
EPS 2 | -0.6400 | -0.6900 | -0.4200 | -0.7000 | -0.6200 | -0.5500 | -0.6300 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 5/26/21 | 3/29/22 | 3/28/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 3.118 | 0.454 | 1.809 | 1.342 | 0.0419 | 0.6228 | 0.8531 | 1.324 | - | - | - | - |
EBITDA | - | - | - | -3.553 | -5.12 | -4.803 | -4.226 | - | - | - | - | - | - |
EBIT 1 | -3.112 | -1.881 | -3.511 | -4.02 | -5.667 | - | -4.511 | -5.078 | -10.77 | - | -6.954 | -6.04 | -5.394 |
Operating Margin | - | -60.33% | -773.37% | -222.2% | -422.45% | - | -724.22% | -595.23% | -813.31% | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.173 | - | -2.75 | -3.914 | -5.419 | - | -4.304 | -4.939 | -10.68 | - | -6.954 | -6.04 | -5.394 |
Net income 1 | -3.173 | - | -3.511 | -3.914 | -5.419 | -5.071 | -4.304 | -4.939 | -10.68 | -7.468 | -6.954 | -6.04 | -5.394 |
Net margin | - | - | -773.25% | -216.37% | -403.93% | -12,107.66% | -691.13% | -578.91% | -806.69% | - | - | - | - |
EPS 2 | -0.0900 | -0.0600 | -0.1000 | -0.1100 | -0.1500 | -0.1400 | -0.1200 | -0.1400 | -0.3000 | -0.2000 | -0.1800 | -0.1300 | -0.1200 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/29/22 | 5/13/22 | 8/12/22 | 11/7/22 | 3/28/23 | 5/9/23 | 8/11/23 | 11/14/23 | 4/1/24 | 5/15/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | 0.05 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 5/26/21 | 3/29/22 | 3/28/23 | 4/1/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.76% | 40.47M | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- HCWB Stock
- Financials HCW Biologics Inc.